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Background: Phelan-Mc Dermid syndrome is a contiguous disorder resulting from 22q13.3 deletion implicating the
SHANK3 gene. The typical phenotype includes neonatal hypotonia, moderate to severe intellectual disability, absent
or delayed speech, minor dysmorphic features and autism or autistic-like behaviour. Recently, point mutations or
micro-deletions of the SHANK3 gene have been identified, accompanied by a phenotype different from the initial
clinically description in Phelan McDermid syndrome.
Case presentation: Here we present two case studies with similar psychiatric and genetic diagnosis as well as
similar clinical history and evolution. The two patients were diagnosed with autism spectrum disorders in childhood
and presented regression with catatonia features and behavioural disorders after a stressful event during
adolescence. Interestingly, both patients presented mutation/microdeletion of the SHANK3 gene, inducing a
premature stop codon in exon 21. Different pharmacological treatments (antipsychotics, benzodiazepines, mood
stabilizer drugs, antidepressants, and methylphenidate) failed to improve clinical symptoms and lead to multiple
adverse events. In contrast, lithium therapy reversed clinical regression, stabilized behavioural symptoms and
allowed patients to recover their pre-catatonia level of functioning, without significant side effects.
Conclusion: These cases support the hypothesis of a specific SHANK3 phenotype. This phenotype might be linked
to catatonia-like deterioration for which lithium use could be an efficient treatment. Therefore, these cases provide
an important contribution to the field of autism research, clinical genetics and possible pharmacological answers.
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Autism Spectrum Disorders (ASD) include a wide range
of phenotypes represented by a continuum from slight
to severe dysfunction of social interaction and commu-
nication as well as restrictive and stereotyped behaviour
[1]. Among multiple etiologies of ASD, studies underlie
a strong genetic component with mutations and dele-
tions described in multiple genes [2]. The SHANK3 gene
on chromosome 22q13.3 appears to be of special interest
as it is implicated in about 2% of ASD patients with in-
tellectual deficiency [3]. SHANK3 is a post-synaptic scaf-
folding protein, involved in the regulation of the* Correspondence: serret.s@pediatrie-chulenval-nice.fr
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unless otherwise stated.structural organization of dendritic spines, and a binding
partner of neuroligins [4].
Deletions of chromosome region 22q13.3 including
the SHANK3 gene are responsible of the clinical mani-
festations of Phelan–McDermid syndrome (PMS) [5].
This syndrome is characterized by neonatal hypotonia,
moderate to severe intellectual disability (ID), absent or
delayed speech, minor dysmorphic features and autism
or autistic-like behaviour. In addition, a clinically signifi-
cant progressive loss of skills, atypical bipolar disorders,
catatonia and behavioural disorders have been described
[6-9]. The SHANK3 gene is thought to play a major role
for neurobehavioral phenotype, clinical evolution and
neurological deterioration in PMS [7]. Interestingly, re-
cent advances suggest that SHANK3 mutations may lead
to different phenotypes than PMS, which have not yet
been clearly identified [3].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion/microdeletion of the SHANK3 gene. Both patients
presented regression, catatonia features and behavioural
disorders. Importantly, clinical symptoms were reversed
by lithium therapy, after failure and multiple side effects of
other psychotropic medications (Additional files 1 and 2).
Case presentations
Case 1
Patient 1 is a 21-year-old man with ASD diagnosis based
on the DSM-5 criteria as well as on the Autism Diagnos-
tic Interview-Revised (ADI-R) [10] and the Autism Diag-
nostic Observation Schedule (ADOS) [11]. He is the
second child of non-consanguineous parents and had no
perinatal history. He was first evaluated at age 6 (see
Table 1). At the verbal level, his language was limited to
simple vocabulary of everyday life, with literal compre-
hension. He used words and short sentences to make a
request and presented echolalia and stereotypic lan-
guage. At the cognitive level, he has severe intellectual
disability. At the motor level, he had no early psycho-
motor delay and liked to do sports and practiced biking
for several hours a week. At age 13, as he moved from
usual autism day-care centre to a non-specific autism
unit, major clinical changes were observed.
From age 13 to 15: regression and behavioural disorders
In the following, patient 1 progressively reduced motor
and verbal initiative, stopped his favourite activities, pre-
sented a language regression and lost autonomy skills.
Additionally, behavioural disorders (impulsive acts, un-
predictable gesture and opposition) alternated with ap-
athy. At last, sleep disturbances and insomnia appeared.Table 1 Summary of patients’ early development and
first evaluation (y: years, m: months)
Patient 1 Patient 2
Diagnosis (DSM 5) ASD ASD
Early development
Perinatal history No No
Walking (y,m) 1,2 1,3
Cleanliness day and night (y) 3 3
Language (first words) (y,m) 3,5 2,3
Age of first evaluation 6 9
Autism intensity (CARS-T) 36 34.5
Intellectual level (Terman-Merill) (y,m) 2,9 2,9
Speech delay, echolalia, stereotypical language yes yes
Vineland I : Communication (y,m) 2,3 2,8
Daily living skills (y,m) 2,4 2,1
Socialization (y,m) 1,8 2,3From age 15 to 19: catatonia symptoms and side effects
of medications
At age 15, behavioural disorders required a hospitalization
in an inpatient child and adolescent psychiatric unit.
Neurological evaluation including brain Magnetic Reson-
ance Imaging (MRI) and Electroencephalography (EEG) as
well as biological analysis did not show any abnormalities.
Genetic evaluation diagnosed a microdeletion of 4 bases in
exon 21 of the SHANK3 gene (c.3653_3656delCCCT), re-
sponsible of a premature stop codon (p.Ser1218CysfsX81).
Patient 1 received different psychotropic medications
which were partially effective but accompanied by mul-
tiple side effects. (1) Antipsychotics were able to control
aggressive behaviours and insomnia, but induced catato-
nia with positive evaluation by Bush Francis Catatonia
Rating Scale (BFCRS) [12] and elevated muscle enzymes
(creatine phosphokinase = 1286 UI/l, normal <175, and
lactate dehydrogenase = 735 UI/l, normal: 200–480). (2)
Benzodiazepines reduced catatonia symptoms but didn’t
control impulsive actions, and induced verbal and motor
excitement, confusion and insomnia. (3) Mood stabilizer
drugs had no clinical efficacy and induced somatic prob-
lems such as cytolysis with valproic acid, and DRESS syn-
drome (Drug Reaction with Eosinophilia and Systemic
Symptoms) with carbamazepine. (4) Antidepressants
didn’t show any efficacy. (5) Among multiple drug associa-
tions only the co-therapy of aripiprazole and clonazepam
showed partial efficacy improving regression, autonomy,
language and motor skills for about 12 months, but with-
out behaviour stabilization. (5) Methylphenidate was not
effective and induced insomnia, violence and shouting.
(6) Lithium was initially introduced in association with
other psychotropic drugs (e.g. methylphenidate) and for a
short period (<2 months), without clear clinical effects.
From age 19 to 21: lithium therapy and reversion of
symptoms
As there was no symptoms improvement, the diagnosis of
atypical bipolar disorders was suspected. Therefore, it was
decided to re-introduce lithium (1500 mg/day), only asso-
ciated with melatonin (4 mg/day). In the following, symp-
toms progressively stabilized during the next 3 months.
Agitation, hetero-aggressiveness and impulsivity disap-
peared. The patient regained autonomy in everyday life,
and urinary and faecal incontinence stopped. In addition,
the patient did no longer show opposition and participated
again in different activities with other patients. Finally, he
began riding his bike again. As the patient did no longer
present sleep disturbances, melatonin could be stopped
after 3 months of lithium therapy. With a follow-up of
2 years, lithium treatment permitted to reverse regression
and to stabilize behavioural disorders and is well tolerated
(1500 mg/day, blood lithium level =0.8 mEq/l, normal:
0.6-1). One year after the beginning of lithium therapy,
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ered a level of functioning similar to the level he had be-
fore regression (see Figure 1 and Figure 2).
Case 2
Patient 2 is a 17-year-old female adolescent with ASD
diagnosis based on the DSM-5 criteria as well as on
ADI-R and ADOS. She has first evaluation at age 9 (see
Table 1). She is the only child of non-consanguineous
parents without perinatal history. At the verbal level, she
presented echolalia and stereotypic language with words
and short sentences used in everyday life and in context.
At the cognitive level, she has severe intellectual disabil-
ity. At the motor level, she had no early psychomotor
delay and she liked sports, especially rock climbing and
gym. At age 12, major clinical changes were observed at
the same time as she changed the day-care centre for a
specific autism unit.From age 13 to 15: regression and behavioural disorders
After age 12, the patient presented regression and be-
havioural disorders. She lost night urinary autonomy,
slowly reduced her initiative affecting motor and verbal
skills, and developed impulsive and aggressive behav-
iours against other children. In the following, the patient
modified her body posture getting vaulted and remained
frequently motionless needing physical stimulation in order
to be able to move. At last, she presented deterioration of
skills and autonomy, urinary and faecal incontinence as wellFigure 1 Clinical Global Improvement - Severity and - Improvement scale at
Impression scale (CGI) has two components: the CGI-Severity (CGI-S), which is
and the CGI-Improvement (CGI-I), which assesses the change of patient’s illne
worse) [18].as sleep disturbances (insomnia). Brain MRI, EEG and bio-
logical analysis were normal. The genetic evaluation found
a point mutation in exon 21 of the SHANK3 gene
(c.2425G >T) responsible of a premature stop codon
(p.Glu809X).From age 15 to 16: catatonia features and side effects
of medication
The clinical presentation suggested the diagnosis of
catatonia-like symptoms without the full picture of catato-
nia (negative evaluation by BFCRS and normal blood ana-
lyses including muscle enzymes). In line with this
hypothesis, we decided to introduce benzodiazepine treat-
ment with clonazepam (0.9 mg/day). The patient rapidly
improved and regained motor abilities, normal body pos-
ture, language, participation, and autonomy in a few
months. Sleep disturbances and faecal incontinence
stopped but night urinary incontinence persisted. These
improvements continued for about 8 months. However,
verbal and motor excitement progressively increased. Sur-
prisingly, the patient progressively lost weight whereas she
continued to ate normally (loss of 8 kg in 8 months) and
without other clinical symptoms such as vomiting. Her ini-
tial body mass index (BMI) of 19.7 decreased to 16.4. We
therefore decided to progressively withdrawal clonazepam.
During the 4 following months, the patient regained weight
(BMI =18.1), but then regressed again by losing motor and
verbal skills. At last, she presented once more catatonia-
like symptoms including behavioural disorders (hetero-different time points of the follow-up of patient 1. The Clinical Global
a seven-point scale rating severity of illness (1-normal to 7-extremely ill)







Diagnosis (at age 6) Before regression During regression After regression
(Lithium use)
Vineland Adaptative Behavior Scale
Age Equivalents for Patient 1 
Communication Daily Living Skills Socialization
Figure 2 Vineland Adaptative Behavior Scale Age Equivalents for patient 1. The Vineland Adaptive Behavioral Scale (VABS) [19] was used to
measure the level adaptive of functioning (Communication, Daily Living Skills and Socialization). VABS age equivalents are expressed in months
(Y-axis) at different time points of the follow-up of patient 1 (diagnosis, before, during and after regression).
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was re-introduced. Two days after, motor and verbal ex-
citement, sudden impulsive actions, and total insomnia
were observed requiring hospitalization in the inpatient
psychiatric unit. Clonazepam was switched to loraze-
pam (3 mg/day), complicated by confusion, faecal in-
continence, agitation and insomnia.Figure 3 Clinical Global Improvement – Severity (CGI-S) and - ImprovemenFrom age 16 to 17: lithium therapy and reversion
of symptoms
Based on the clinical similarities between patient 1 and
2, our clinical experience with patient 1 and the hypoth-
esis of atypical bipolar disorder, we decided to introduce
lithium, associated with very low dose clonazepam
(0.2 mg/day). Patient 2 stabilized behavioural symptomst scale (CGI-I) at different time points of the follow-up of patient 2.
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participation, sleep and autonomy. However, night urinary
incontinence persisted. Clonazepam was discontinued
after 4 months. After one year with lithium treatment
(1000 mg/day, lithium blood level 0.7 mEq/l, normal 0.6-
1), the patient recovered a similar level of functioning as
before regression (see Figure 3 and Figure 4). Lithium re-
versed regression and stabilized behavioural disorders
without side effects.
Conclusion
The two patients described in this article had a similar
psychiatric (ASD) and genetic diagnosis (mutation/
microdeletion of the SHANK3 gene inducing a prema-
ture stop codon in exon 21) as well as similar clinical,
history and evolution (regression with catatonia features
after a stressful event in adolescence). In contrast, mul-
tiple psychotropic medications were partially or not ef-
fective and accompanied by important side effects.
Finally, lithium therapy permitted reversibility of regres-
sion and catatonia, and the stabilization of behavioural
disorders without significant side effects.
Unlike most clinical descriptions of patients presenting
SHANK3 deletions and Phelan–McDermid syndrome,
our patients present a somewhat different phenotype
which might be linked to the size and location of the
molecular anomalies [3,13]. There was no history of
hypotonia and the motor level permitted the regular
practice of sports [5]. The progressive loss of skills (ver-
bal, motor and autonomy) associated with catatonia fea-











Figure 4 Vineland Adaptative Behavior Scale Age Equivalents for patient 2
time points of the follow-up of patient 2 (diagnosis, before, during and aftesuggestive of “catatonia-like deterioration” described in
ASD patients after a stressful event [14].
Nevertheless, we describe for the first time two cases
for which reversibility of those symptoms was found
after lithium treatment. Lithium is a mood stabilizer
drug with a long history in psychiatry. It is mainly used
in adult patients to treat manic episodes in bipolar dis-
order and for treatment-resistant depression [15]. Our
finding of clinical efficacy of lithium is in line with the
recent idea that SHANK3 patients with ASD may
present an atypical form of bipolar disorders [8,9]. Im-
portantly, lithium therapy was proposed after several
therapeutic failures leading to severe side effects. Indeed,
studies suggest that SHANK3 ASD patients might be
more vulnerable to psychotropic drugs than other ASD
patients [7]. In addition, lithium has been identified hav-
ing an action on synaptic modulation with a possible
neuroprotective role in neurodegenerative diseases [16].
Lithium might be a rescue therapy for some patients
presenting shankopathies by partially reversing impaired
synaptic function and neural circuit defects [17]. Further
clinical and biological studies are required to explore
this hypothesis.
The current report underlines the importance of
building bridges between genetics and clinical follow-up,
not only for further understanding of genetic psychiatric
disorders but also for treatment decisions. While this re-
port presents limitations (two cases and after only one
year), it opens new avenues to the study of shankopa-
thies for which phenotype descriptions and treatment
recommendations are still sparse.During regression After regression
(Lithium use)
e Behavior Scale 
s for Patient 2 
iving Skills Socialization
. VABS age equivalents are expressed in months (Y-axis) at different
r regression).
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